| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
1-(-D-Xylofuranosyl)uracil manufacturers
|
| | 1-(-D-Xylofuranosyl)uracil Basic information |
| Product Name: | 1-(-D-Xylofuranosyl)uracil | | Synonyms: | 1-(-D-Xylofuranosyl)uracil;Xylo-uridine;1-(beta-D-Xylofuranosyl)uracil;2,4(1H,3H)-Pyrimidinedione, 1-β-D-xylofuranosyl-;1-(b-D-xylofuranosyl)uracil;1-(b-D-Xylofuranosyl)uracil, Xylo-uridine, impurity;Uridine Impurity 49;1-Xylosyluracil | | CAS: | 16535-78-7 | | MF: | C9H12N2O6 | | MW: | 244.2 | | EINECS: | | | Product Categories: | | | Mol File: | 16535-78-7.mol |  |
| | 1-(-D-Xylofuranosyl)uracil Chemical Properties |
| Melting point | 158-158.5 °C(Solv: ethanol (64-17-5)) | | density | 1.674±0.06 g/cm3(Predicted) | | pka | 9.39±0.10(Predicted) |
| | 1-(-D-Xylofuranosyl)uracil Usage And Synthesis |
| Uses | 1-(β-D-Xylofuranosyl)uracil is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005
[2] Connolly GP, et al. Uridine and its nucleotides: biological actions, therapeutic potentials. Trends Pharmacol Sci. 1999 May;20(5):218-25. DOI:10.1016/s0165-6147(99)01298-5 |
| | 1-(-D-Xylofuranosyl)uracil Preparation Products And Raw materials |
|